Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Average Rating of “Moderate Buy” from Analysts
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among […]
